Targets › CNR2
42 programs from 29 companies in 54 trials: 32 Phase 1, 19 Phase 2, 2 Phase 3, 1 Phase 4; Psychiatry, Neurology, Other; next expected readout Nov 2026.
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis. (UniProt, P34972)
Open in Phaseline: the race on CNR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alasht Pharmed | Canvert-M Topical cannabidiol with essential oils (peppermint, lavender, rosemary, eucalyptus, winte | CNR1, CNR2 | Phase 4 | Migraine Disorders | – |
| University of Colorado, Denver | THC/CBD Cannabinoid receptor agonist (THC and CBD) | CNR1, CNR2 | Phase 3 | Back Pain | Jun 2027 |
| Vertanical | VER-01 Cannabis sativa extract containing Δ9-tetrahydrocannabinol (THC) - cannabinoid receptor ag | CNR1, CNR2 | Phase 3 | Lumbosacral Radiculopathy | Sep 2028 |
| IGC Pharma | IGC-AD1 Delta-9-tetrahydrocannabinol (THC) | CNR1, CNR2 | Phase 2 | Alzheimer Disease | Nov 2026 |
| University of Manitoba | MPL-001 Cannabidiol-enriched cannabis with THC 2 mg/ml and CBD 50 mg/ml; targets cannabinoid recep | CNR1, CNR2 | Phase 2 | Chronic Migraine; Childhood Cancer | Dec 2026 |
| Federal University of Latin American Integration | Oral Cannabis Extract (Full-Spectrum) Cannabinoid CB1 and CB2 receptor agonist | CNR1, CNR2 | Phase 2 | Psoriasis Vulgaris; Alzheimer Disease (AD) | Feb 2027 |
| BC Centre on Substance Use | Aurora 1:1 Drops (Indica) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 1:1 ratio | CNR1, CNR2 | Phase 2 | Opioid Use Disorder | Mar 2027 |
| Incannex Healthcare | IHL-42X Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an | CNR1, CNR2, CA2 | Phase 2 | Obstructive Sleep Apnea (OSA) | Apr 2027 |
| University Medical Center Groningen | Medical Cannabis Oil Cannabinoid mixture containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | CNR1, CNR2 | Phase 2 | Hepatocellular Carcinoma | Apr 2027 |
| Brown University | CBD-dominant cannabis Cannabinoid receptor modulator (CBD-dominant preparation with 0.35% THC and 11.27% CBD) | CNR1, CNR2 | Phase 2 | Alcohol Drinking | Aug 2027 |
| Brown University | THC-dominant cannabis Cannabinoid CB1 and CB2 receptor agonist (THC-dominant preparation with 9.53% THC and 0.09 | CNR1, CNR2 | Phase 2 | Alcohol Drinking | Aug 2027 |
| Southwest Autism Research & Resource Center | MB-IMP CBD (cannabidiol) and THC (tetrahydrocannabinol) mixture; CBD is a non-selective cannabino | CNR1, CNR2 | Phase 2 | Autism Spectrum Disorder | Sep 2027 |
| Bazelet Nehushtan | Terpenes-Enriched CBD-Predominant Oil (T1/C28) Cannabinoid system modulation with CBD and minor THC with terpenes | CNR1, CNR2 | Phase 2 | Autism | Dec 2027 |
| Yale University | CBD 300mg (Nantheia™ ATL5 300mg) Cannabidiol - cannabinoid receptor modulator | CNR1, CNR2 | Phase 2 | Chronic Pain | Jan 2028 |
| VA Office of Research and Development | THC (Syndros) Cannabinoid receptor agonist (CB1 and CB2) | CNR1, CNR2 | Phase 2 | Neuropathic Pain | Sep 2028 |
| VA Office of Research and Development | THC + CBD (Nabiximols) Combination cannabinoid receptor agonist (CB1 and CB2) plus cannabidiol | CNR1, CNR2 | Phase 2 | Neuropathic Pain | Sep 2028 |
| University of Calgary | CBD 200 mg OD Cannabinoid receptor agonist | CNR1, CNR2 | Phase 2 | Chronic Migraine | Dec 2028 |
| NeuroTherapia | NTRX-07 CB2 agonist | CNR2 | Phase 2 | Alzheimer Disease | – |
| Zynerba Pharmaceuticals | ZYN002 Cannabidiol transdermal gel | CNR1, CNR2 | Phase 2 | Fragile X Syndrome | – |
| Murdoch Childrens Research Institute | C12T12 Ruby Balanced Oil Cannabinoid mixture containing THC and CBD | CNR1, CNR2 | Phase 1 | Palliative Care | Nov 2026 |
| Murdoch Childrens Research Institute | C20T5 Ruby CBD Oil Cannabinoid mixture containing CBD and THC | CNR1, CNR2 | Phase 1 | Palliative Care | Nov 2026 |
| University of California, Los Angeles | Vaporized Beta-Caryophyllene (0.5 mg) Cannabinoid CB1/CB2 receptor agonist | CNR1, CNR2 | Phase 1 | Pain | Nov 2026 |
| University of California, Los Angeles | CBG (Cannabigerol) Cannabinoid receptor agonist | CNR1, CNR2 | Phase 1 | Pain | Dec 2026 |
| University of California, Los Angeles | THC (Tetrahydrocannabinol) Cannabinoid receptor agonist | CNR1, CNR2 | Phase 1 | Pain | Dec 2026 |
| Yale University | Delta-9-THC Very Low Dose Cannabinoid CB1 and CB2 receptor agonist | CNR1, CNR2 | Phase 1 | Cannabis; Age-related Cognitive Decline; Schizophrenia | Dec 2026 |
| Universidade do Sul de Santa Catarina | Full-spectrum CBG oil 30 mg/mL Full-spectrum Cannabis extract containing cannabigerol (CBG), cannabidiol (CBD), and tetra | CNR1, CNR2, GPR55 | Phase 1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Dec 2026 |
| Florida A&M University | Full-Spectrum CBD hemp extract oral solution Cannabinoid-rich botanical extract with multi-target anti-inflammatory and neuroprotective | CNR1, CNR2 | Phase 1 | Diabetic Peripheral Neuropathic Pain (DPN) | Dec 2026 |
| Universidade do Sul de Santa Catarina | Full-spectrum CBD oil 100 mg/mL Cannabidiol (CBD) and tetrahydrocannabinol (THC) from Cannabis sativa extract; CBD is a no | CNR1, CNR2 | Phase 1 | Major Depressive Disorder (MDD) | Dec 2026 |
| University of Manitoba | MPL-005 Cannabidiol-enriched cannabis herbal extract (1:5 THC:CBD ratio) | CNR1, CNR2 | Phase 1 | Childhood Cancer | Dec 2026 |
| University of Manitoba | MPL-009 Balanced cannabis herbal extract (1:1 THC:CBD ratio) | CNR1, CNR2 | Phase 1 | Childhood Cancer | Dec 2026 |
| University of California, Los Angeles | THC + CBD Combination of cannabinoid receptor agonist (THC) and cannabinoid receptor modulator (CBD) | CNR1, CNR2 | Phase 1 | Drug Abuse | Jun 2027 |
| Shanna Babalonis, PhD | Inhaled vaporized cannabis Cannabinoid receptor agonist (low THC formulation) | CNR1, CNR2 | Phase 1 | Opioid Use Disorder; Cancer | Jun 2027 |
| University of California, Los Angeles | CBD 40 mg Cannabinoid receptor modulator; non-competitive antagonist at CB1 | CNR1, CNR2 | Phase 1 | Abuse, Drug | Sep 2027 |
| University of California, Los Angeles | CBD 80 mg Cannabinoid receptor modulator; non-competitive antagonist at CB1 | CNR1, CNR2 | Phase 1 | Abuse, Drug | Sep 2027 |
| Washington State University | THC 20mg Cannabinoid receptor agonist | CNR1, CNR2 | Phase 1 | Cannabis Use | May 2028 |
| Staci Gruber, Ph.D. | Custom-formulated, high-CBD study product Full-spectrum hemp-derived high-CBD product | CNR1, CNR2 | Phase 1 | Endometriosis | Jan 2029 |
| Johns Hopkins University | THC 5mg Cannabinoid CB1/CB2 receptor agonist | CNR1, CNR2 | Phase 1 | Cannabis Use | Apr 2029 |
| Johns Hopkins University | THC Low Dose Cannabinoid receptor agonist | CNR1, CNR2 | Phase 1 | Cannabis Use | Apr 2029 |
| Milton S. Hershey Medical Center | CBG/CBD Oil Cannabinoid receptor agonist (CBG/CBD blend with CBC) | CNR1, CNR2 | Phase 1 | Chemotherapy-Induced Peripheral Neuropathy | Apr 2029 |
| University of California, San Diego | BRC-002 Cannabidiolic acid (CBDA) and CBD with minor cannabinoids | CNR1, CNR2 | Phase 1 | Complex Regional Pain Syndrome | Jun 2029 |
| University of British Columbia | Cannabis oil with a high ratio of THC to CBD Cannabinoid receptor agonist (THC-dominant) | CNR1, CNR2 | Phase 1 | Healthy | – |
| McMaster University | Tetrahydrocannabinol (THC) Partial agonist of cannabinoid receptors CB1 and CB2 | CNR1, CNR2 | Phase 1 | Cannabis | – |
Pain (4) Cannabis Use (3) Cannabis (3) Childhood Cancer (3) Cancer (3) Alzheimer Disease (2) Alcohol Drinking (2) Opioid Use Disorder (2) Abuse, Drug (2) Psoriasis Vulgaris (2) Chronic Migraine (2) Neuropathic Pain (2)
small molecule (41)
University of California, Los Angeles (6) University of Manitoba (3) Brown University (2) Johns Hopkins University (2) Universidade do Sul de Santa Catarina (2) VA Office of Research and Development (2) Yale University (2) Murdoch Childrens Research Institute (2) IGC Pharma (1) BC Centre on Substance Use (1) Zynerba Pharmaceuticals (1) Florida A&M University (1) Federal University of Latin American Integration (1) University of Colorado, Denver (1) Southwest Autism Research & Resource Center (1) Washington State University (1) Milton S. Hershey Medical Center (1) University of British Columbia (1) University of Calgary (1) McMaster University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.